BLENOXANE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLENOXANE (bleomycin) is a small-molecule injectable chemotherapy agent approved in 1973. The specific indications are not documented in available data, but bleomycin is historically used in oncology for various malignancies. It functions as an antibiotic-derived chemotherapeutic with DNA-damaging properties.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BLENOXANE offers limited career growth opportunity as a legacy injectable approaching LOE with zero linked job postings. Roles available are primarily defensive—focused on compliance, manufacturing continuity, and managed decline rather than innovation or expansion.
Product Manager (Legacy)Sales Representative
Worked on BLENOXANE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.